Oncology

A Biosimilar Adoption Program Saved a US Nonprofit Health System $29.6M in 2 Years

July 23rd 2022

By Deana Ferreri, PhD

Article

The first 2 years of the program created $26.9 million in cost savings and “biosimilar adoption rates that greatly exceed the US national average."

Alvotech to Launch Pharmacokinetics Study for Denosumab Biosimilar

July 20th 2022

By Mary Caffrey

Article

The biosimilar candidate would reference Prolia, used in the treatment of osteoporosis in postmenopausal women and to treat bone loss in adult men and women who are at increased risk of fracture. It is also planned as a biosimilar for Xgeva, which is indicated to prevent skeletal fractures in patients with cancer.

Posters Assess Quality of Trastuzumab, Denosumab Biosimilars in Cancer

July 19th 2022

By Skylar Jeremias

Article

Posters from the American Society of Clinical Oncology’s annual meeting showed the safety and efficacy of a trastuzumab biosimilar and a denosumab biosimilar in different types of cancer.

Rituximab Biosimilars Prove Effective in Large B-Cell Lymphoma

July 14th 2022

By Skylar Jeremias

Article

Abstracts from the European Hematology Association Congress 2022 confirmed comparable safety and effectiveness profiles between 2 rituximab biosimilars and the reference product (Rituxan) in patients with large B-cell lymphoma.

Report: Biosimilar Uptake Accelerates in US—and So Do the Savings

July 13th 2022

By Mary Caffrey

Article

Amgen's early view said health care savings from the use of these biologic therapies climbed to $3 billion in the second quarter of 2022, for total of $18 billion over the past 6 years.

Survey: Most Patients Received Inadequate Information About Switching to a Trastuzumab Biosimilar

July 9th 2022

By Deana Ferreri, PhD

Article

A survey study found that many patients with breast cancer reported receiving inadequate information regarding switching from Herceptin to a trastuzumab biosimilar, with some patients reporting that they were never told a switch occurred or what a biosimilar was.

Henlius’ Pertuzumab Biosimilar Shows Similar PK Profile to Reference Product in First Human Study

July 2nd 2022

By Deana Ferreri, PhD

Article

In the first human study of Shanghai Henlius Biotech's pertuzumab biosimilar candidate (HLX11), investigators found similar pharmacokinetic (PK), safety, and immunogenicity profiles between the biosimilar and the reference product (Perjeta).

ASCO Studies Assess Biosimilar Substitution, Adoption in Oncology Practices

June 16th 2022

By Skylar Jeremias

Article

Abstracts from the American Society of Clinical Oncology (ASCO) annual meeting took a look at the impact biosimilar substitution and increased biosimilar adoption had on spending within practices participating in value-based payment models and the Oncology Care Model.

Eye on Pharma: New Indication for Riabni, Organon and Henlius Partner on 2 Biosimilar Candidates

June 14th 2022

By Skylar Jeremias

Article

The FDA granted a new indication for rheumatoid arthritis for Riabni, a rituximab biosimilar, and Organon and Shanghai Henlius Biotech entered into a licensing agreement for 2 oncology biosimilar candidates.

Similar Effectiveness, Safety of Biosimilar CT-P6 vs Reference Trastuzumab in Retrospective Study

June 13th 2022

By Deana Ferreri, PhD

Article

An analysis of retrospective data demonstrated comparable safety and efficacy profiles between CT-P6, a trastuzumab biosimilar, and Herceptin (reference trastuzumab) combined with chemotherapy and pertuzumab.